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For the first time ever, an international consensus statement for infection prevention and control
in PCD is presented. A total of 20 statements were developed in a collaboration of BEAT-PCD, COST
Action, ERS CRC and ERN-LUNG PCD Core Network. https://bit.ly/3yuahKt
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Abstract
Introduction In primary ciliary dyskinesia (PCD) impaired mucociliary clearance leads to recurrent airway
infections and progressive lung destruction, and concern over chronic airway infection and patient-to-
patient transmission is considerable. So far, there has been no defined consensus on how to control
infection across centres caring for patients with PCD. Within the BEAT-PCD network, COST Action and
ERS CRC together with the ERN-Lung PCD core a first initiative has now been taken towards creating
such a consensus statement.
Methods A multidisciplinary international PCD expert panel was set up to create a consensus statement
for infection prevention and control (IP&C) for PCD, covering diagnostic microbiology, infection
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prevention for specific pathogens considered indicated for treatment and segregation aspects. Using a
modified Delphi process, consensus to a statement demanded at least 80% agreement within the PCD
expert panel group. Patient organisation representatives were involved throughout the process.
Results We present a consensus statement on 20 IP&C statements for PCD including suggested actions for
microbiological identification, indications for treatment of Pseudomonas aeruginosa, Burkholderia cepacia
and nontuberculous mycobacteria and suggested segregation aspects aimed to minimise patient-to-patient
transmission of infections whether in-hospital, in PCD clinics or wards, or out of hospital at meetings
between people with PCD. The statement also includes segregation aspects adapted to the current
coronavirus disease 2019 (COVID-19) pandemic.
Conclusion The first ever international consensus statement on IP&C intended specifically for PCD is
presented and is targeted at clinicians managing paediatric and adult patients with PCD, microbiologists,
patient organisations and not least the patients and their families.
Introduction
Primary ciliary dyskinesia (PCD, MIM244400) is a heterogeneous recessive, or rarely dominant autosomal
or X-linked disorder, exhibiting dysfunction of motile cilia causing disease in various organ systems [1].
To date, mutations in >57 genes are known to be associated with motile ciliopathies, the vast majority
causing PCD [1, 2] and the number is continuously increasing. Dyskinetic multiple motile cilia lining the
airways cause impairment of mucociliary clearance inducing recurrent and chronic infections of the upper
and lower airways. Common symptoms in PCD comprise late onset respiratory distress syndrome in
neonates, and chronic wet cough, recurrent and chronic otitis media with hearing impairment, sinusitis and
recurrent or chronic bronchitis throughout childhood and adulthood, as well as male infertility. Persistent
airway infection and inflammation lead to destructive pulmonary changes such as chronic collapsed and
destroyed lobar segments and bronchiectasis [3] and may further result in end-stage lung disease, and
rarely need for lung transplantation and premature death [4], thus to some extent manifestations similar to
those of cystic fibrosis (CF).
Patients with PCD are frequently chronically infected with bacterial pathogens similar to those in CF [5],
and in adult patients with PCD Pseudomonas aeruginosa infection has been shown to be more prevalent
than Haemophilus influenzae infection [6], which underlines that P. aeruginosa is a pathogen of great
concern also in patients with PCD and that the airway microbiology of patients with PCD seems to mirror
that of CF [7]. This has enabled the extrapolation of information from CF airway microbiology to PCD,
including assumptions of the need for similar management of pulmonary infections ranging from use of
intensive antibiotic therapy regimens to IP&C, despite little evidence [8–10].
Retrospective data suggest that chronic infection with P. aeruginosa is associated with worse lung disease in
PCD, similar to what is known in CF [11]. Even though there is currently no clear evidence for
patient-to-patient transmission of P. aeruginosa between individuals with PCD, cross-infection in PCD is still
a major concern extrapolated from compelling evidence of patient-to-patient transmission in CF [12, 13],
especially involving P. aeruginosa [14]. Failure to detect chronic infections could be caused by poor quality
of airway secretion samples or due to infrequent and inconsistent sampling of airway secretion from the
patients [5], or the laboratory may miss pathogens that require special culture conditions, e.g. Achromobacter
species, Burkholderia species and nontuberculous mycobacteria (NTM).
Although PCD shares clinical features with CF and non-CF bronchiectasis, it is important to acknowledge
the fundamental differences in pathophysiology, symptoms and prognosis between these different diseases
[14, 15].
Healthcare providers and patient organisations sometimes encourage educational activities in PCD
comprising face-to-face meetings involving multiple patients and their families, and patients could also be
involved in group activities, such as pulmonary rehabilitation, where they may come into contact with
other patients. However, CF patient associations/foundations have imposed strict requirements to avoid
cross-infection during patient participation in different contexts [16], and we therefore recognise the
importance to reflect on advice for people with PCD.
With lack of specific evidence and consensus, PCD clinicians have generally applied CF treatment
principles and to some extent adult non-CF bronchiectasis principles [8]. However, a general scepticism
among PCD physicians that complete adoption of CF treatment and prevention measures is appropriate has
led to inconsistencies, uncertainties and generally less strict versions of strategy for patients with PCD.
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Consequently, a workshop was held at a “BEAT-PCD” academic meeting and training school in Valencia
2017 aiming to develop the framework for a consensus statement for infection prevention and control
(IP&C) for PCD to guide paediatric and adult PCD care providers, microbiologists handling specimens
from patients with PCD, and patients and patient organisations, covering aspects of microbiological
diagnostics, infection prevention for specific pathogens considered indicated for treatment and segregation
aspects in PCD. The overall mission of “BEAT-PCD” (Better Experimental Approaches to Treat PCD;
COST Action BM1407; and ERS Clinical Research Collaboration) is to promote networking and
multidisciplinary clinical and translational research with the goal to improve diagnosis and treatment
improving long-term outcome of patients with PCD.
The current work was also done in collaboration with the ERN-LUNG PCD core, established by the
European Reference Network (https://ern-lung.eu).
The aim of these consensus statements was to provide specific suggestions as how to overall improve
infection prevention and infection control in PCD, whereas specific antimicrobial therapy was considered
outside the scope of this document.
Patient representatives were included throughout the process of conducting the presented consensus
statements.
Methods
Developing the framework for an IP&C consensus statement for PCD
The panel was invited with the aim of covering as many countries and experts as possible and with equal
experience in paediatric and adult PCD, and at the same time with the expectation of personal attendance
at the first meeting. The panel consisted of 22 experts and 2 patient representatives – 20 clinicians from
16 countries including 14 paediatric pulmonologists responsible for both paediatric and adult patients, one
adult chest physician exclusively managing adults with PCD, one respiratory physiotherapist, and one
microbiologist; clinicians were from across Europe (Northern, Southern, Western and Eastern areas
represented), the Middle East and Australia.
During the initiating face-to-face working group discussion in Valencia 2017, it was agreed that there was
a need to develop a specific IP&C for PCD and that the process should include the use of E-surveys in
combination with face-to-face meetings. It was decided that the preparation and implementation of the
consensus should include the following steps: 1) literature search and generation of a list of relevant items;
2) prioritising the items; and 3) discussion of these items during face-to-face meetings and voting for
statements sent out via an internet-based E-survey system. The E-survey responses were to be evaluated
using a modified Delphi process that differed from the original Delphi process [17] by allowing
face-to-face meetings and opting out anonymity. This combined use of expert-panel face-to-face meetings
and E-surveys in a modified Delphi process had previously been used successfully in the BEAT-PCD
organisation for creating an international consensus statement on defining pulmonary exacerbations in PCD
[18] and for developing an international consensus statement for transmission electron microscopy criteria
in the diagnostics of PCD [19]. In addition, people with PCD and representatives from PCD patient
organisations were to be invited to give their opinion by e-mail during the process and before finalising the
consensus statement document.
The literature search was focused with an aim to support each specific statement and included search
words for PCD combined with search words representing microbiological diagnostics, infection prevention
and control, infection management and clinical impact of infection. The literature search was expanded to
also include and combine search words for CF, non-CF bronchiectasis and for managing acute and chronic
airway infections and infection in these clinical entities.
The process of reaching consensus
E-surveys
Proposed statements were presented to the PCD expert panel according to the Delphi method by use of an
anonymous E-survey. For each statement, respondents could choose the answer on a Likert scale including
the following terms: “strongly agree”, “agree”, “neutral”, “disagree” or “strongly disagree” or choose not to
give an opinion. Respondents were encouraged to elaborate by using a comment field if they chose
“neutral” or one of the disagreement possibilities to ensure future surveys could address and build on
disagreements. Consensus to a statement was defined as at least 80% agreement (“strongly agree” or
“agree”) among the voters within the PCD expert panel group.
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Face-to-face meetings
In between E-surveys the expert panel met for face-to-face meetings to discuss the results of agreed
statements and evaluate on statements not yet agreed. After thorough discussion, each statement not yet
accepted would either be modified and re-phrased or discarded.
COVID-19 pandemic influence
The consensus process ended in October 2019, prior to the start of the COVID-19 pandemic.
Owing to the worldwide restrictions and overall changed social habits caused by the COVID-19 pandemic,
it was decided that statements regarding segregation issues that had not initially reached consensus should
be revisited and evaluated again by the expert panel as the opinions could have changed in the light of this
new situation. The statements were not re-phrased but simply re-circulated by e-mail to the PCD expert
panel for re-evaluation.
Results
Over a 2-year period from September 2017 to October 2019 a group of 25 international PCD experts were
invited to evaluate specific PCD consensus statements covering diagnostic microbiology, indications for
infection treatment (IT) and segregation (S) aspects with the aim to create an international consensus
statement for managing IP&C in PCD.
The original IP&C consensus work was performed before the COVID-19 pandemic and consisted of 30
proposed statements from which 19 statements reached consensus after the original consensus process that
ended October 2019. Additionally, one statement regarding social behaviour and segregation in PCD
settings that was initially rejected before the COVID-19 pandemic was subsequently accepted in its
original form after a re-evaluation in September 2020 amidst the COVID-19 pandemic. Hence, consensus
was finally reached on 20 statements that are presented here as the first ever consensus statement for IP&C
in PCD. The flow of the consensus process is illustrated in figure 1.
Literature search results
A total of 11 studies were retrieved from the literature search that concerned prevalence, clinical impact
and management of P. aeruginosa infection in patients with PCD [5, 6, 9, 11, 20–26].
Prevalence of P. aeruginosa in patients with PCD ranged from 9% to 47%, the prevalence increasing with
age [5, 23–25].
Three observational studies showed worse computed tomography (CT) scan scores in patients with PCD
chronically infected with P. aeruginosa compared to non-infected patients [6, 11, 20], whereas convincing
impact of P. aeruginosa infection on lung function was not consistently found among four included
studies [11, 23, 25], as only one study out of four showed decreased forced expiratory volume in 1 s
(FEV1) in P. aeruginosa-infected patients.
One study based on an online survey questionnaire described considerable variation in how P. aeruginosa
infection was managed across 43 PCD centres in 26 European countries and also that only a few centres
had written guidelines for PCD management [9].
Two studies were concerning prevalence of NTM infection in PCD and reported a prevalence of 3% in
children [23] and 10% in adults [24], respectively.
Achromobacter xylosoxidans was shown to be a pathogen primarily identified among adult patients with
PCD in a single study of a mixed population including both children and adults with PCD in which
A. xylosoxidans was recovered in 6% of samples from adults older than 25 years versus only in 1% of
samples from children below 12 years of age [5]. No other studies were identified in the literature search
that concerned prevalence, impact or management of A. xylosoxidans.
No studies were identified in the literature search that concerned prevalence, impact or management of
Burkholderia cepacia in PCD.
There were no studies identified concerning IP&C and control of lung infections in PCD.
https://doi.org/10.1183/23120541.00301-2021 4
ERJ OPEN RESEARCH ORIGINAL RESEARCH ARTICLE | J.K. MARTHIN ET AL.
Working Group formation by invitation in Valencia 2017
Appointing PCD expert panel and setting up an IP&C for PCD
Face-to-face meeting in Milan 2017
Discussion on proposed statements before sending out first E-survey
E-Survey 1
30 proposed statements sent out to PCD expert panel members
Face-to-face meeting in Lisbon 2018
Discussion of E-Survey 1 results and re-phrasing for E-Survey 2
E-Survey 2#
15 re-phrased proposed statements sent out to PCD expert panel members
Face-to-face meeting in Poznan 2019
Discussion of E-Survey 2 results and re-phrasing for E-Survey 3
E-Survey 3#
10 re-phrased proposed statements sent out to PCD expert panel members
Face-to-face meeting in Madrid 2019
Working Group presents 19 final specific IP&C PCD statements
A total of 7 proposed
statements were finally 
rejected after E-survey 
1+2+3 (table 2)
4 proposed statements 
were excluded early in 
the consensus process
September 2020 after hit of COVID-19 pandemic




1 agreed statement (wearing of face 
mask and keeping social distance)
PCD expert panel agreed on 20
final specific IP&C PCD statements
in September 2020 (table 1)
FIGURE 1 Consensus process of the infection prevention and control (IP&C) for primary ciliary dyskinesia (PCD) international consensus statement using a modified Delphi process including
both E-surveys and face-to-face meetings. A total of 20 statements were agreed for the final IP&C statement (presented in table 1). A total of seven proposed statements were excluded after
finalising the process of E-survey 1+2+3 and the face-to-face meetings (presented in table 2). A total of four proposed statements were excluded early on from the further consensus process.




















Initiating face-to-face meeting: BEAT-PCD Valencia meeting April 2017
At this initiating meeting 17 PCD experts participated. Another eight experts who were absent were
subsequently invited to join the process by e-mail. The 17 experts attending the meeting were asked
whether they agreed on the need for developing a consensus for IP&C for PCD and 14 out of 17 (82%)
TABLE 1 Final 20 suggested BEAT-PCD consensus statements included in the infection prevention and control for primary ciliary dyskinesia (PCD)
statements




1 DM “The BEAT-PCD network suggests to culture on selective media for Pseudomonas aeruginosa routinely in
every airway secretion sample#”
100 18
2 DM “The BEAT-PCD network suggests that all PCD Centres have access to bacterial typing” 100 14
3 DM “The BEAT-PCD network suggests to culture airway secretion samples# from patients at least 4 times
annually”
94.4 18
4 DM “The BEAT-PCD network suggests to culture for NTM at least annually and in addition at any unexplained
deterioration of lung function”
92.9 14
5 DM “The BEAT-PCD network suggests routine bacterial typing at first positive culture of Burkholderia cepacia” 92.9 14
6 DM “The BEAT-PCD network suggests the use of modified Leeds criteria [5] when defining chronicity of
Pseudomonas aeruginosa”
83.3 18
7 IT “The BEAT-PCD network suggests that treatment of NTM relies on 1) Pulmonary symptoms and 2) Nodular
or cavitary processes on chest radiograph and/or bronchiectasis with small nodules on HRCT scan and
3) Positive culture results from at least two separate airway secretion samples# or positive culture results
from at least one bronchial wash or lavage or mycobacterial histological findings in either transbronchial
or lung biopsy material together with positive microbiological culture according to 2020 ATS/IDSA
criteria” [27]
100 18
8 IT “The BEAT-PCD network suggests that cultured Pseudomonas aeruginosa is treated regardless of symptoms
and microscopy”
100 18
9 IT “The BEAT-PCD network suggests that Haemophilus influenzae, Moraxella catarrhalis, Streptococcus
pneumoniae, Staphylococcus aureus (MSSA) are treated, if the patient is symptomatic”¶
94.4 18
10 IT “The BEAT-PCD network suggests that cultured Multi-Resistant Staphylococcus aureus (MRSA) is treated
regardless of symptoms and microscopy”
86 14
11 IT “The BEAT-PCD network suggests that cultured Burkholderia cepacia complex is treated regardless of
symptoms and microscopy”
83.3 18
12 S “The BEAT-PCD network suggests that patients with Pseudomonas aeruginosa infection should be
segregated in outpatient and in-patient settings”
100 18
13 S “The BEAT-PCD network suggests that patients with NTM infection should be segregated in outpatient and
in-patient settings”
94.4 18
14 S “The BEAT-PCD network suggests that patients with MRSA infection should be segregated in outpatient
and in-patient settings”
88.9 18
15 S “The BEAT-PCD network suggests that patients with Burkholderia cepacia complex infection should be
segregated in outpatient and in-patient settings”
88.9 18
16 S “The BEAT-PCD network suggests that all PCD centres have written guidelines for segregation that are
adapted to the facilities of the individual centres and to the best standards”
94.4 18
17 S+ “During the COVID-19 Pandemic concerning arrangements outside the hospital: The BEAT-PCD network
suggests (e.g., BEAT-PCD Conferences) that if more than one patient with PCD is attending indoor events




18 S “The BEAT-PCD network suggests that patients with identified viral infection or ‘clinically having a cold’
should be temporarily segregated in outpatient and in-patient settings, or at least wear a mask”
88.2 17
19 S “The BEAT-PCD network suggests a cleaning procedure between patients and at the end of the day to
include registered hospital-grade disinfectant/detergent”
83.3 18
20 S “The BEAT-PCD network suggests that the following bacteria do not need specific considerations regarding
segregation: Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae and
Staphylococcus aureus (MSSA)”
82.4 17
DM: diagnostic microbiology aspects; NTM: nontuberculous mycobacteria; IT: infection treatment aspects; HRCT: high-resolution computed
tomography; S: segregational aspects; COVID-19: coronavirus disease 2019; MSSA: methicillin-susceptible Staphylococcus aureus. Voters: 18 PCD
experts responded to the E-surveys; 16 voted by e-mail for consensus statement #15. #: Airway secretion sample defined as: sputum sample or
oropharyngeal cough swab or laryngeal suction. ¶: “Symptomatic” = increased symptoms judged at the discretion of the treating physician.
+: Accepted consensus after re-evaluation due to COVID-19 pandemic. Accepted consensus was based on the decisions from an international PCD
expert panel. Each proposed statement was presented for the expert panel using a Likert scale offering five possible response options: “Strongly
agree”, “Agree”, “Neutral”, “Disagree”, “Strongly disagree”. Consensus for a proposed statement was defined where at least 80% agreement
(“Strongly agree” or “Agree”) was obtained within the PCD expert panel.
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agreed on this. Next, the participants were asked whether to adopt all suggestions from the already existing
IP&C for CF [16] and include those for PCD as well. Only 59% agreed on this, i.e., less than the goal of
achieving 80% agreement. Based on this, it was decided to undertake a survey aiming to develop a
separate IP&C for PCD.
E-surveys and face-to-face meetings
At a BEAT-PCD meeting in Milan, September, 2017 during the ERS International Congress the expert
panel had a face-to-face meeting where initial proposed statements were discussed before sending out the
first E-survey.
E-survey 1 resulted in agreement in 11 of the proposed statements.
Following E-survey 1 a face-to-face meeting was held in Lisbon, February, 2018. The results from the
first E-survey were presented for the expert panel and altered phrasing of statements not yet agreed upon
was discussed for the following E-survey 2.
Four statements were further excluded after evaluating E-survey 1; reasons for exclusion are given below.
E-survey 2 resulted in acceptance of four additional statements, thereby increasing consensus to a total of
15 presented statements.
Face-to-face meeting Poznan, March, 2019: Each of the remaining statements that had not reached
agreement after E-survey 2 were presented to the expert panel again. Based on comments from the expert
panel 10 re-phrased statements were circulated for a third and final E-survey.
E-survey 3: Four additional statements reached agreement within the expert panel, increasing the
consensus to 19 statements.
Face-to face meeting Madrid, October, 2019 at a BEAT-PCD meeting held during the ERS International
Congress: The 19 final statements were agreed for the IP&C consensus statement.
COVID-19 influence: E-mail correspondence with the PCD expert panel during the COVID-19
pandemic, September, 2020. One previously rejected statement regarding segregation now reached
consensus after e-mail re-visiting of statements regarding segregation. This lastly accepted statement
involved suggested wearing of a face mask and keeping a distance of at least 2 m during indoor patient
meetings.
TABLE 2 Seven rejected statements not included in the infection prevention and control for primary ciliary dyskinesia (PCD) consensus statements
No. Aspect Statement Consensus
%
Voters
1 DM “The BEAT-PCD network suggests use of Gram-staining and microscopy as part of clinical microbiological
diagnostics at PCD centres where this service is available”
78.6 14/18
2 DM “The BEAT-PCD network suggests investigating for viral respiratory infections in case of a clinical
exacerbation”
72.8 18/18
3 DM “The BEAT-PCD network suggests routine bacterial typing at first positive culture of Achromobacter
xylosoxidans”
71.4 14/18
4 DM “The BEAT-PCD network suggests routine bacterial typing at first positive culture of Pseudomonas
aeruginosa”
57.2 14/18
5 IT “The BEAT-PCD network suggests that cultured Achromobacter xylosoxidans is treated regardless of
symptoms and microscopy”
66.7 18/18
6 S “The BEAT-PCD network suggests that patients with Achromobacter xylosoxidans should be segregated in
outpatient and in-patient settings”
77.8 18/18
7 S “The BEAT-PCD network suggests to always have a 30-minute wait between all PCD patients regardless of
infection status”
72.8 18/18
Seven proposed consensus statements did not reach consensus during the Delphi process. Each proposed statement was presented for the expert
panel using a Likert scale offering five possible response options: “Strongly agree”, “Agree”, “Neutral”, “Disagree”, “Strongly disagree”. “No
consensus” was defined as <80% agreement (“Strongly agree” or “Agree”) within the PCD expert panel. DM: diagnostic microbiology aspects; IT:
infection treatment aspects; S: segregational aspects. Voters: 18 PCD experts responded to the E-surveys.
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With that a total of 20 consensus statements were included for the overall final IP&C for PCD (figure 1).
Accepted consensus statements
Altogether, consensus was reached for 20 out of originally 30 proposed statements (66.7%). Complete
agreement, defined as 100% consensus among voters was achieved on 5 out of 20 agreed statements
(25%), and general consensus defined as at least 80% agreement was achieved on 15 out of 20 (75%) of
agreed statements. Detailed results on agreed consensus statements are summarised in table 1.
In total, consensus was reached on six items considering diagnostic microbiology aspects, five items
considering indication for infection treatment (IT) aspects and nine items considering segregation (S)
aspects. Consensus on the segregation aspect items increased from eight to nine after three selected
originally proposed and discarded statements were revisited after the start of the COVID-19 pandemic.
BEAT-PCD suggestions concerning diagnostic microbiology (DM) aspects
Consensus was reached concerning a number of measures taken to limit infections from opportunistic
pathogens such as P. aeruginosa, B. cepacia and NTM, including early detection of infection by
suggesting at least four airway secretion samples obtained from PCD patients annually as per modified
Leeds criteria for defining chronic P. aeruginosa infection [5], and suggesting specific microbiological
laboratory measures such as extended culture on selective media and access to bacterial typing in order to
increase microbiological diagnostic accuracy.
BEAT-PCD suggestions concerning indication for infection treatment (IT) aspects
Consensus was reached towards suggestion of treating P. aeruginosa, B. cepacia and methicillin-resistant
Staphylococcus aureus (MRSA) regardless of symptoms and NTM according to ATS/ERS/ESCMID/IDSA
criteria from the 2020 guideline [27], and treatment of airway secretion positive patients with H. influenzae,
Moraxella catarrhalis, Streptococcus pneumoniae and S. aureus (MSSA) only if symptomatic. Consensus for
treatment of MRSA followed common guidelines for MRSA eradication [28].
BEAT-PCD suggestions concerning segregation (S)
Consensus was reached towards need for segregation if patients were infected with P. aeruginosa and
B. cepacia complex, MRSA and NTM, whereas no consensus was obtained for suggesting segregation in
patients infected with A. xylosoxidans or patients with positive culture results for H. influenzae,
M. catarrhalis, S. pneumoniae and S. aureus (MSSA).
Social distancing of at least 2 m between patients with PCD and patient use of face masks during indoor
meetings including more than one patient with PCD became the suggestion after the outbreak of
COVID-19, although this was initially rejected during the pre-COVID-19 consensus process.
Rejected statements
Eventually, seven proposed statements remained unagreed and were excluded from the final consensus
statement (table 2). Of particular note we achieved no consensus for indication of treatment or segregation
in case of positive culture of A. xylosoxidans.
Excluded statements
Four proposed statements were excluded early in the process after E-survey 1.
E-survey 1 included a statement suggesting implementing the existing IP&C for CF [16] for PCD.
However, this was turned down as only 9 out of 17 voters agreed (52.9%), i.e. less than the goal of 80%
agreement and thus supporting the development of a specific IP&C for PCD. Therefore, this particular
statement was excluded from the further consensus process. Two proposed statements regarding indication
for treatment and segregation if infected with Stenotrophomonas maltophilia were both turned down in
E-survey 1 (29.4% agreement and 23.5% agreement, respectively) and excluded by agreement among the
expert panel members at the face-to-face meeting following the E-survey 1. The primary reason for the
exclusion was that S. maltophilia is considered a possible “bystander” with little known pathogenic
potential even in patients with CF [29–31]. The fourth excluded statement that proposed routine bacterial
typing of S. aureus if a patient had three or more positive cultures per year was turned down in E-survey 1
(50% agreement) and thus excluded, as it was considered mainly of research interest among the PCD
expert panel members.
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Discussion
Since the description of PCD as a unique disease entity in 1976 [32, 33], management strategies for PCD
have been derived mainly from CF care. This has been considered acceptable, as both represent conditions
with impaired mucociliary airway clearance, and since evidence-based studies designed specifically for
treating PCD have been completely lacking until very recently [34, 35]. Now, with the growing knowledge
of the pathophysiology and natural history of PCD, and the fact that PCD is definitively different from that
of CF, the time has come to create a separate IP&C consensus statement in PCD.
In this consensus statement, we present 20 suggestions regarding microbiology diagnostics, indications for
infection treatment and segregation actions, aiming specifically for better IP&C in patients with PCD
including separate suggestions for infection prevention for specific pathogens considered indicated for
treatment: P. aeruginosa, B. cepacia and NTM as well as H. influenzae, S. pneumoniae, M. catharrhalis
and MSSA/MRSA. Our statement also provides general suggestions for cleaning procedures and
segregation aspects in PCD care.
BEAT-PCD suggestions concerning monitoring and indications for treatment of bacterial airway
infections
A general concern for chronic P. aeruginosa infection in PCD is rational. A substantial prevalence of
P. aeruginosa has been reported in PCD cohorts [5, 23–25], and there are indications of worse CT scan
scores in chronically infected patients with PCD [11, 20] and a risk of further decline of lung function
when chronically infected with P. aeruginosa [11]. Still, the evidence from studies including patients with
PCD and P. aeruginosa infection are sparse and hence our presented suggestions for treating P. aeruginosa
infections were additionally based on the indications of CF and PCD parallelism in airway susceptibility
and bacterial adaptation, as the underlying genetic defects in these two diseases result in impaired
mucociliary clearance [36]. Both diseases lead to increased susceptibility to airway infections,
e.g. H. influenzae, S. aureus and P. aeruginosa. The infections are characterised by adaptation of the
bacterial populations to the site of infection.
In two studies using whole genome sequencing of longitudinally collected P. aeruginosa isolates from
patients with CF and PCD, evidence was found for phenotypic and genotypic parallelism in the evolution
of P. aeruginosa across infected patients. The parallel changes and convergent adaptation and evolution are
believed to be caused by similar selective forces such as the intensive antibiotic treatment and the
inflammatory response, which drive the evolutionary processes [12, 22]. In a selected cohort of 34 CF
patients and 12 patients with PCD similar convergent evolution was identified in eight genes related to
antibiotic resistance, quorum sensing, motility, Type III secretion and mucoidity [12, 22].
All in all, the concern of clinical impact together with the predicted parallelism in bacterial behaviour in
CF and PCD patients justified a well-founded concern of P. aeruginosa infection and is now reflected in
the present BEAT-PCD consensus statement for close airway secretion monitoring, indication for treatment
and segregation of patients infected with P. aeruginosa to limit its spread. Parallel suggestions for
treatment of B. cepacia were proposed, primarily due to a concern derived from CF experience, as
B. cepacia has only been rarely described in PCD and no studies on PCD and B. cepacia infection were
identified in our literature search.
For the treatment of NTM, BEAT-PCD agreed to adopt the criteria from the ATS/ERS/ESCMID/IDSA
guideline [27] as described in table 1. In alignment with these treatment criteria, BEAT-PCD also suggests
culturing for NTM at least annually [37] and at the time of any unexplained deterioration of lung function.
Consensus was not reached on suggesting indication for treatment or segregation of patients with a positive
culture for A. xylosoxidans, the main argument for rejection being the rarity of documented
A. xylosoxidans infection in PCD, no published studies on A. xylosoxidans infection in PCD and overall
lack of experience within the expert panel group. In CF, chronic infection with A. xylosoxidans has been
associated with lung function decline [38, 39] and patient-to-patient transmission [40, 41], which raises the
concern that A. xylosoxidans infection may also play an ignored but significant role in PCD. Future studies
to investigate the impact of A. xylosoxidans in PCD are certainly warranted.
BEAT-PCD suggestions concerning adoption of Leeds criteria for defining chronicity of P. aeruginosa
The most commonly used definition for P. aeruginosa status in CF epidemiological research is that from
the Leeds criteria [7], and although it may not be optimal in all circumstances and may, in some cases,
lead to the misinterpretation of a chronic infection for an intermittent infection [42, 43], these criteria were
considered as the most suitable definition at present.
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The expert panel decided to adopt a modified version [5] of the original Leeds criteria established for CF [7]
to define chronicity of P. aeruginosa in the current IP&C statement for PCD. The original Leeds criteria [7]
define “chronic infection” when >50% of the preceding 12 months’ cultures are positive for the specific
pathogen and “intermittent infection” when 50% or less of the preceding 12 months’ cultures have been
positive for the specific pathogen and “free of infection” when no growth has occurred in the lungs in the
previous 12 months. According to the modification of these criteria used in the current statements, the patient
should provide at least four samples of airway secretion per year [5].
Within the expert panel concerns were raised for not being able to diagnose chronic infections due to poor
quality of airway secretion samples or due to infrequent and inconsistent sampling of airway secretion. An
additional concern was that the sinuses in patients with PCD can function as a bacterial reservoir for
recurrent lung infection, including hosting P. aeruginosa [21]. The suggested requirement of four annual
samples of airway secretion is in alignment with previous recommendations for pulmonary care and
monitoring for PCD [10]. Although it may seem difficult to achieve, the expert panel believes that regular
monitoring is the only way to detect, for example, P. aeruginosa at the earliest timepoint possible and have
chosen to keep the bar at this higher level in recognition that an even more frequent monitoring is certainly
further optimal, but probably difficult to implement.
BEAT-PCD suggestions concerning segregation inside and outside hospital settings
The BEAT-PCD IP&C consensus statement suggests segregation inside and outside hospital settings if the
patient has a known infection with P. aeruginosa, B. cepacia, NTM or MRSA even at first positive isolate.
At present there is no clear evidence for patient-to-patient transmission of P. aeruginosa between patients with
PCD. However, transmission of non-susceptible strains of P. aeruginosa between CF patients has been a
well-known problem since first described in 1986 [44]. From the experience in CF, it is also known that some
clone types have the potential to spread to other patients, e.g. patients with COPD. Therefore, all direct contact
between individuals with CF is generally suggested to be avoided whether inside or out of the hospital [45, 46].
Since at least four samples of airway secretion per year is also suggested, the last positive airway secretion
culture could be 3 months old or more. Hence, there will be a potential risk for transmission of these
unwanted pathogens if they were contracted more recently than the last airway secretion sample.
A consideration to minimise this risk could be to ask patients to send their airway secretion sample a week
before their outpatient appointment to allow any change of infection status to be known on the day of the
patients’ appointments. It should, however, be noted that slow-growing pathogens in a sample may bias
culture results owing to overgrowth of more fast-growing bacteria with the risk of not detecting the
pathogenic bacteria if present in small amounts.
A 30-min gap between all PCD patient appointments regardless of infectious status that could otherwise
minimise transmission did not reach consensus as it was perceived too difficult to adhere to due to
logistics at various sites.
It has been suggested that non-CF bronchiectasis patients managed within a CF service centre should be
managed according to the same strict infection control procedures as patients with CF, because of the risk
of transmission from the CF patients to the non-CF bronchiectasis patients and vice versa [14]. This
concern for transmission was not evaluated in the current BEAT-PCD IP&C statement. However, shared
facilities between patients with CF and those with PCD do occur in some of the PCD centres, and
adherence to the strict CF segregation rules should be considered in these centres.
The statements on segregation are more far-reaching based on a precautionary principle and more detailed
with regard to both bacteria and viruses and in line with IP&C for CF [16] and clearly deviate from
recommendations regarding bronchiectasis in general [47].
BEAT-PCD suggestions concerning cleaning procedures in hospital settings
Cleaning of the patient-room between appointments and at the end of the day with registered
hospital-grade disinfectant/detergent was suggested to avoid the general spread of microorganisms to other
patients. According to World Health Organization (WHO) guidelines, healthcare personnel must also
perform hand hygiene before entering the room and when leaving the room of a patient, before or after
direct contact with a patient, before putting gloves on and after removing gloves, for sterile and nonsterile
procedures, after contact with a patient’s skin, mucous membranes, respiratory secretions or other body
fluids, and after contact with medical equipment near the patient that may be contaminated with respiratory
secretions [48].
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BEAT-PCD suggestions concerning wearing a mask and keeping a 2-m distance at outside hospital
patient events
The overall concern for cross-infection of, for example, P. aeruginosa between patients with PCD led to
this proposed statement. Use of face masks had previously been shown to be effective at reducing the
release of potentially infective Pseudomonas-containing aerosols in patients with CF [49, 50], and wearing
a face mask is suggested for CF in healthcare settings [51]. However, our PCD patient representatives
raised concerns of stigmatisation by wearing masks and also that highly valued meetings between patients
outside the hospital would be too difficult to organise, and therefore the opportunity for mutual support
and face-to-face exchange of experiences could get lost. Partly due to this patient concern, the proposed
statement was initially rejected but later accepted following the COVID-19 outbreak. Currently, during the
COVID-19 pandemic, wearing a mask has become commonly suggested and widely used among most
people in all daily life situations and hence stigmatism is currently not an issue. In addition, many larger
patient meetings will currently not be possible due to the general assembly restrictions in most countries. It
is, however, important to stress that this issue had been clearly controversial before the COVID-19
pandemic, since both PCD experts and patient’s representatives were reluctant to accept the suggestion.
Whether the suggestion should be removed from the statement once the COVID-19 pandemic is under full
control remains open, and the board of PCD experts and patient’s representatives should be consulted
again when this time comes [52].
Limitations of the study
Members of the expert panel were mainly paediatric pulmonologists, whereas representation from
physicians managing adult PCD was low, which could lead to the concern that adult patients were not
appropriately represented. However, adult PCD care has traditionally been managed by paediatricians in
many PCD centres for many years, and almost 75% of the medical experts in the present consensus panel
have extensive experience in management of both children and adults with PCD.
Many of the consensus statements grew out of extrapolation of evidence based on CF because of the lack
of current evidence in the field of PCD, although extrapolation from a whole different disease entity such
as CF can never be optimal. Crafting evidence specifically for PCD is of extreme importance and will also
be possible in the near future owing to currently growing PCD registries, more randomised controlled trials
to come and further multicenter observational studies in PCD cohorts. In the current situation and for lack
of anything better, we found that the Delphi method used was appropriate in achieving the presented
statements concerning PCD.
There is currently no evidence regarding patient-to-patient transmission of NTMs and no evidence
regarding the risk associated with infection of specific NTM species in PCD. However, from the
experience across the expert panel it was clear that NTMs indeed are sometimes cultured and also in some
cases cause clinical symptoms and radiological changes in patients with PCD. Based on these experiences,
the expert panel chose to include statements suggesting indication of treatment as per ATS/ERS/ESCMID/
IDSA 2020 guidelines [27], which include treatment strategies for a number of NTM species. In alignment
with this and due to lack of evidence in PCD we chose not to differentiate between specific NTMs in the
statements. Similarly, the expert panel chose to suggest segregation whenever any NTM species is
cultured.
We consider these IP&C statements as a guide for all physicians who manage paediatric and adult patients
with PCD, whether it takes place in a dedicated PCD centre, a centre where the experts in addition to CF
also manage PCD or where PCD patients constitute a minority among larger numbers of patients with all
sorts of other diagnoses within adult pulmonary medicine.
Conclusion
We here provide the first International BEAT-PCD IP&C consensus statement for PCD within COST
Action and ERS Clinical Research Collaboration together with the ERN-LUNG PCD Core Network.
The consensus statement consists of 20 suggestions for IP&C intended specifically for patients with PCD
in a number of settings. The statements are targetted at paediatric and adult PCD healthcare providers,
microbiologists, PCD patient organisations and patients themselves. Patient representatives were included
throughout the process of conducting the presented consensus statements. The statements include
suggestions for microbial diagnostics, infection prevention for specific pathogens considered indicated for
treatment, and segregation strategies for outpatient and inpatient settings as well as for non-healthcare
settings.
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